

## Harbour BioMed presents HBICE Platform, an HCAb Based Immune Cell Engager

01 September 2020 | News

### New Platform HBICE (Heavy chain only antibody (HCAb) Based Immune Cell Engager) presented at 16th PEGS Boston Summit



Harbour BioMed, a global, clinical-stage, innovative biopharmaceutical company, has launched its newly developed HBICE™ (HCAb Based Immune Cell Engager) platform. The platform is capable of generating fast and reliable next-generation bispecific antibodies for immunotherapies.

The HCAb platform can generate diverse and stable fully human HCAs derived human VH single-domain moieties, that allow for the design of novel multi-specific and multi-valent antibodies in simplified structures with relatively smaller molecule size and fewer number of polypeptide chains. Leveraging the technology know-how, we accumulated on our HCAb, we have independently developed the HBICE™ Platform, which focuses on generating highly differentiated HCAb-based immune cell engagers capable of delivering tumor-killing effects unachievable by combination therapies. As the only proven bispecific mechanism of action in oncology, immune cell engagers engage patients' own immune cells to identified tumor-specific antigen cells, with the goal of activating the cytotoxic potential of immune cells to fight cancers. Compared with other bispecific formats for immune cell engagers bispecifics generated on HBICE™ platform are able to address multiple criteria critical to clinical activity of bispecifics. The versatile geometry designs based on biology MoAs, fully human amino-acid sequences, intact Fc-mediated long half-life and other unique properties make HBICE™ an effective and efficient bispecific or multi-specific antibody platform.

HBICE™ enables the facile development of products with attributes not achievable by conventional antibody platforms or a simple combination of two monoclonal antibodies. In this poster we demonstrate how the HBICE™ platform generates high efficiency Tumor Associated Antigen (TAA) x 4-1BB bispecific antibodies, which co-stimulate T Cells, inhibit tumor growth and maintain an improved safety profile comparing to other conventional monoclonal antibodies. Several additional targets based on this platform are currently in discovery and preclinical stages of development.

The poster was presented through a voice-over presentation on August 31 at the 16th PEGS Boston virtual Summit. The event is happening from August 31 to September 4, 2020